Home플랫폼과 전략논문 &학회발표
PEGS 2019 / The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation
ASCO 2019 / Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer
PEGS 2017 / Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001